Icon

RAPAMUNE (nda021083)- (1MG/ML)

SIROLIMUS PF PRISM CV
1MG/ML
No No
2014-Mar-30 Expired
2022-May-28 None
None No
• Rapamune is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged ≥13 years receiving renal transplants: o Patients at low-to moderate-immunologic risk: Use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2-4 months after transplantation. o Patients at high-immunologic risk: Use in combination with CsA and corticosteroids for the first 12 months following transplantation. Safety and efficacy of CsA withdrawal has not been established in high risk patients. • Rapamune is an mTOR inhibitor indicated for the treatment of patients with lymphangioleiomyomatosis.
5 0 5
Total Other Developers 5
Drugs with Suitability No
1MG/ML ** ** - - 4
NDA Sales Available Total Generic Sales Available
Yes 4
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ******** ****** ******** ****** *** *********** ** **** *****, **** *******, *** ****** (**) *****, ****** ****** (***) ***
****** ****** ****** ***************, *** *********** ** ********** ** **** *, **********, *** ****** (**) *****-****, ****** ****** (***) ***
****** ****** ****** ***. *********** *** ****** *****, *******, ******* *** ***, ****** (***) ***
****** ******* **** ************** *** *********** ** ***** ********* **, ********, *** ****** (**) *****, ****** ****** (***) ***
****** *** *** *************** *** *********** **, **** ****, **********, *** ****** (**) *****, ****** ****** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.